<div id="readability-page-1"><p>In a report released today, Ami Fadia from Needham maintained a Buy rating on Bicycle Therapeutics, with a price target of <span id="expert-recommendation-target">$15.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Fadia covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Neurocrine, and Bicycle Therapeutics. According to TipRanks, Fadia has an average return of <span>30.8%</span> and a 56.80% success rate on recommended stocks. </p> <p>In addition to Needham, Bicycle Therapeutics also received a Buy from TD Cowen’s Tara Bancroft in a report issued on April 30. However, on May 1, Truist Financial maintained a Hold rating on Bicycle Therapeutics (NASDAQ: BCYC).</p></div>

BCYC

<p>Needham's Ami Fadia has reaffirmed a Buy rating on Bicycle Therapeutics (BCYC) with a price target of $15.00. Fadia, who specializes in the Healthcare sector, has an average return of 30.8% and a 56.80% success rate on stock recommendations. Additionally, TD Cowen's Tara Bancroft also rated BCYC as a Buy, while Truist Financial maintained a Hold rating on the stock.</p>

Needham Reaffirms Their Buy Rating on Bicycle Therapeutics (BCYC)